about
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective ...
Read More
1.83
0.11
(6.40%)
459.8K
XNAS Volume
XNAS 09 Dec, 2025 4:30 PM (EST)
Not Eligible
Expensive Valuation
Technically Neutral
MEI Pharma Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..